Solventum Corporation $SOLV Shares Acquired by LSV Asset Management

LSV Asset Management increased its position in shares of Solventum Corporation (NYSE:SOLV) by 364.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,122 shares of the company’s stock after acquiring an additional 27,561 shares during the quarter. LSV Asset Management’s holdings in Solventum were worth $2,564,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the company. CYBER HORNET ETFs LLC purchased a new position in Solventum during the second quarter worth about $28,000. Deseret Mutual Benefit Administrators grew its stake in shares of Solventum by 78.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after buying an additional 163 shares during the period. MUFG Securities EMEA plc acquired a new stake in shares of Solventum during the 2nd quarter worth approximately $31,000. IMG Wealth Management Inc. purchased a new stake in shares of Solventum during the 2nd quarter valued at approximately $31,000. Finally, State of Wyoming acquired a new position in Solventum in the second quarter valued at approximately $33,000.

Solventum Stock Down 0.5%

Shares of NYSE:SOLV opened at $75.59 on Tuesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The firm has a market capitalization of $13.11 billion, a PE ratio of 8.71, a price-to-earnings-growth ratio of 6.94 and a beta of 0.35. The firm’s 50-day moving average is $79.88 and its two-hundred day moving average is $76.15. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $88.20.

Solventum declared that its Board of Directors has approved a stock buyback plan on Thursday, November 20th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to reacquire up to 7.5% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on SOLV shares. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Mizuho set a $100.00 target price on shares of Solventum and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. Seven investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $90.83.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.